Axsome Therapeutics, Inc. (AXSM) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong near-term catalyst stack: FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on 2026-04-30/05-01, Q1 2026 product revenue rose 57% YoY to $191.2M, NDA submitted for AXS-12, SUNOSI patent settlement extended protection, and the stock is up about 33% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Gross Margin ⢠Cash Burn ⢠Thin Equity AXSM shows strong product economics with ~92% gross margins and net cash, but persistent operating losses, negative free cash flow, and a thin equity cushion keep execution and balance-sheet risk high.
Price Behavior
Key Price Behavior Insights: ⢠Uptrend intact ⢠Rebound support ⢠Resistance cap Support Level: $230-$231, then $222-$224 Resistance Level: $235-$236 Over the last month, AXSM has maintained a constructive uptrend and defended pullbacks, but repeated stalling at $235-$236 shows momentum is improving without a confirmed breakout.
Sentiment & News
Key News Insights: ⢠AUVELITY launch ⢠Litigation resolved ⢠Investor outreach Axsome's latest headlines highlight continued momentum in AUVELITY/SYMBRAVO commercialization and clinical visibility, while the SUNOSI litigation settlement removes a key legal overhang.
AI Summary
AXSM is now a real commercial story rather than a pure pipeline bet, but the investment hinges on whether AUVELITY's label expansion can drive operating leverage fast enough to offset heavy SG&A, negative free cash flow, and a valuation that already prices in strong execution.
Description
Axsome Therapeutics is a U.S.-based biopharmaceutical company developing treatments for central nervous system disorders. Its late-stage pipeline includes a depression candidate (AXS-05) with additional trials in Alzheimer's-related agitation and prior smoking cessation data, a migraine treatment that completed Phase III testing (AXS-07), and Phase III programs for narcolepsy (AXS-12) and fibromyalgia (AXS-14). The company has a research collaboration with Duke University and was founded in 2012 in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 5 | May 12 | AXSM | Axsome Therapeutics, Inc. | Strong near-term catalyst stack: FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on 2026-04-30/05-01, Q1 2026 product revenue rose 57% YoY to $191.2M, NDA submitted for AXS-12, SUNOSI patent settlement extended protection, and the stock is up about 33% over 21 trading days. | Closed | +0.4% |
| Jan 1 | Jan 8 | AXSM | Axsome Therapeutics, Inc. | Axsome Therapeutics is a hot idea with key upcoming FDA priority review of AXS-05 and NDA filing for AXS-12, strong Q3 revenue growth, and robust technical momentum. Despite operating losses and governance risks, its near-term regulatory catalysts provide potential for significant short-term price appreciation. | Closed | -8.3% |